Avalyn Pharma (NASDAQ:AVLN - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

Several other analysts have also issued reports on the company. Evercore began coverage on Avalyn Pharma in a report on Tuesday, May 26th. They set an "outperform" rating and a $51.00 target price on the stock. Weiss Ratings started coverage on Avalyn Pharma in a research note on Thursday, August 13th. They issued a "sell (d+)" rating for the company. Zacks Research raised shares of Avalyn Pharma to a "hold" rating in a research report on Wednesday, May 27th. Morgan Stanley increased their price objective on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Thursday, August 13th. Finally, Guggenheim began coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a "buy" rating and a $80.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $60.00.

Read Our Latest Research Report on AVLN

Avalyn Pharma Stock Down 5.7%

Shares of AVLN stock opened at $31.52 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The firm has a market capitalization of $1.40 billion and a price-to-earnings ratio of -1.38. The stock has a 50-day moving average price of $33.33. Avalyn Pharma has a 12 month low of $24.15 and a 12 month high of $40.17.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.03) by $0.05. Sell-side analysts predict that Avalyn Pharma will post -3.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Braidwell LP bought a new stake in Avalyn Pharma during the 2nd quarter worth approximately $26,382,000. Montanova Capital LLC bought a new position in shares of Avalyn Pharma during the second quarter valued at $82,402,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Avalyn Pharma during the second quarter valued at $1,321,000.

About Avalyn Pharma

(Get Free Report)

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn's lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.

See Also

• Five stocks we like better than Avalyn Pharma
• Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing
• Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits
• These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories
• Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Avalyn Pharma Right Now?

Before you consider Avalyn Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalyn Pharma wasn't on the list.

While Avalyn Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here